[go: up one dir, main page]

MXPA03008823A - Metodos, compuestos y composiciones para reducir la grasa corporal y modular el metabolismo de los acidos grasos. - Google Patents

Metodos, compuestos y composiciones para reducir la grasa corporal y modular el metabolismo de los acidos grasos.

Info

Publication number
MXPA03008823A
MXPA03008823A MXPA03008823A MXPA03008823A MXPA03008823A MX PA03008823 A MXPA03008823 A MX PA03008823A MX PA03008823 A MXPA03008823 A MX PA03008823A MX PA03008823 A MXPA03008823 A MX PA03008823A MX PA03008823 A MXPA03008823 A MX PA03008823A
Authority
MX
Mexico
Prior art keywords
compounds
fatty acid
methods
compositions
body fat
Prior art date
Application number
MXPA03008823A
Other languages
English (en)
Inventor
Rodriguez De Fonseca Fernando
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MXPA03008823A publication Critical patent/MXPA03008823A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Se proporcionan metodos, composiciones farmaceuticas y compuestos para reducir el peso corporal, modular el metabolismo de lipidos corporales y reducir la racion alimenticia en mamiferos. Los compuestos de la invencion incluyen compuestos de etanolamida de acidos grasos, homologos y analogos de los cuales el prototipo es la etanolamida de acidos grasos endogenos, oleoiletanolamida.
MXPA03008823A 2001-03-27 2002-03-27 Metodos, compuestos y composiciones para reducir la grasa corporal y modular el metabolismo de los acidos grasos. MXPA03008823A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27954201P 2001-03-27 2001-03-27
US33628901P 2001-10-31 2001-10-31
PCT/US2002/009773 WO2002080860A2 (en) 2001-03-27 2002-03-27 Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism

Publications (1)

Publication Number Publication Date
MXPA03008823A true MXPA03008823A (es) 2004-08-12

Family

ID=26959730

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03008823A MXPA03008823A (es) 2001-03-27 2002-03-27 Metodos, compuestos y composiciones para reducir la grasa corporal y modular el metabolismo de los acidos grasos.

Country Status (11)

Country Link
US (3) US6911474B2 (es)
EP (1) EP1408945A4 (es)
JP (1) JP2004526745A (es)
KR (1) KR20030087657A (es)
CN (1) CN1523982A (es)
AU (1) AU2002338329B2 (es)
CA (1) CA2442683A1 (es)
EA (1) EA006556B1 (es)
IL (1) IL158131A0 (es)
MX (1) MXPA03008823A (es)
WO (1) WO2002080860A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050154064A1 (en) * 2001-03-27 2005-07-14 The Regents Of The University Of California Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism
WO2002080860A2 (en) 2001-03-27 2002-10-17 The Regents Of The University Of California Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
DE10129693A1 (de) * 2001-06-22 2003-01-02 Jan Loock Verfahren zur extrakorporalen qualitativen und/oder quantitativen Erfassung neurotoxischer Substanzen im Blutplasma eines Individuums
CA2475630C (en) † 2002-02-12 2011-01-18 Hunza Di Pistolesi Elvira & C. S.A.S. N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
WO2004034968A2 (en) * 2002-08-20 2004-04-29 The Regents Of The University Of California Combination therapy for controlling appetites
US7765162B2 (en) * 2002-10-07 2010-07-27 Mastercard International Incorporated Method and system for conducting off-line and on-line pre-authorized payment transactions
US20040157932A1 (en) * 2002-11-18 2004-08-12 Natural Asa, Supplements and foods comprising oleylethanolamide
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
EP1570752B1 (en) * 2004-03-06 2008-07-02 Cognis IP Management GmbH Verwendung von ungesättigten Fettsäuren zur Verringerung des Appetits oder der Essensaufnahme
JP2006061086A (ja) * 2004-08-27 2006-03-09 Morishita Jintan Kk 脂肪代謝改善効果を有する被験試料のスクリーニング方法
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US20090054526A1 (en) * 2005-07-14 2009-02-26 Hansen Harald S Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders
CA2681668C (en) 2006-03-23 2014-04-01 Michael S. Singer Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat
PE20071221A1 (es) * 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
SI1971862T1 (sl) * 2006-04-11 2011-02-28 Arena Pharm Inc Postopki uporabe GPR119 receptorja za identificiranje spojin, uporabnih za povečanje kostne mase pri posamezniku
WO2009033050A1 (en) * 2007-09-07 2009-03-12 University Of Pittsburgh-Of The Commonwealth Sys Tem Of Higher Education Diagnostic and therapeutic uses of augmenter of liver regeneration in inflammatory conditions
ES2291147B1 (es) * 2007-10-15 2008-11-01 Fundacion Instituto Mediterraneo Para La Biotecnologia Y La Investigacion Sanitaria (Imabis) Derivados pirazolicos de amidas de acidos grasos como activadores especificos de receptores ppar-alfa, procedimiento de preparacion y utilizacion.
EP2108960A1 (en) * 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
MX2010012682A (es) * 2008-05-19 2010-12-15 Nestec Sa Metodos para reducir la absorcion de lipidos por un animal.
AU2011229969A1 (en) * 2010-03-24 2012-09-20 Nestec S.A. Methods for enhancing the palatability of comestible compositions
CA2800301C (en) 2010-07-02 2018-03-27 Helix Biomedix, Inc. N-acyl amino acid derivatives for treating skin conditions such as cellulite
EP2982373B1 (en) 2011-01-19 2018-06-13 Topokine Therapeutics, Inc. Methods and compostions for reducing body fat
US20140193370A1 (en) * 2011-05-10 2014-07-10 Nestec Sa Methods and compositions for promoting lean body mass growth
MX2013012990A (es) * 2011-05-10 2013-12-06 Nestec Sa Metodos y composiciones para preservar la masa corporal magra durante la perdida de peso.
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
CN102579414A (zh) * 2012-01-29 2012-07-18 厦门大学 油酰乙醇胺作为降血脂、防治非酒精性脂肪肝药物的用途
WO2013160492A1 (es) * 2012-04-24 2013-10-31 Fundación Instituto Mediterráneo Para El Avance De La Biotecnología Y La Investigación Sanitaria (Imabis) Terapia combinada para el tratamiento de enfermedades metabólicas
US9221747B2 (en) 2012-04-25 2015-12-29 Iowa State University Research Foundation, Inc. Method of making fatty acid N-acylalkanolamines
CN102675141A (zh) * 2012-05-04 2012-09-19 庄信修 N-(2-羟基乙基)芥酰胺及其制备与用途
JP2015534544A (ja) 2012-09-07 2015-12-03 ネステク ソシエテ アノニム オレオイルエタノールアミド組成物
CN102824338A (zh) * 2012-09-18 2012-12-19 厦门大学 s-油酰丙醇胺在制备降血脂、防治非酒精性脂肪肝药物中的用途
CN104936595A (zh) 2012-11-21 2015-09-23 托普凯恩制药公司 局部增加体脂肪的方法和组合物
CN103113253A (zh) * 2013-01-28 2013-05-22 国家海洋局第三海洋研究所 一种不饱和脂肪酸醇胺衍生物及其制备方法与应用
ES2498521B1 (es) * 2013-02-20 2015-08-18 Fundación Pública Andaluza Para La Investigación De Málaga En Biomedicina Y Salud (Fimabis) Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad
NO2753788T3 (es) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
MY172113A (en) 2017-07-05 2019-11-14 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US10702487B2 (en) 2017-08-19 2020-07-07 Frimline Private Limited Pharmaceutical composition for prevention of diet induced obesity
MY186286A (en) 2017-09-05 2021-07-05 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
WO2024124172A1 (en) * 2022-12-09 2024-06-13 The Trustees Of The University Of Pennsylvania Compositions and methods for stimulating and/or enhancing exercise motivation and/or physical performance

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8505569D0 (sv) * 1985-11-25 1985-11-25 Aco Laekemedel Ab Enteralt preparat
US5506224A (en) * 1991-12-31 1996-04-09 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes
US5679667A (en) * 1992-04-24 1997-10-21 Lifegroup S.P.A. Aminoalcohols-N-Acyl derivatives as therapeutical agents against the neurogenic endoneural edema of the peripheral nerve
US5602164A (en) * 1992-04-28 1997-02-11 Senyorina Ltd. Anti-obesity drugs
US5554646A (en) * 1992-04-29 1996-09-10 Wisconsin Alumni Research Foundation Method for reducing body fat in animals
US5618955A (en) 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
IL103932A (en) 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
US5631297A (en) 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
IT1271266B (it) * 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
IT1274783B (it) * 1994-12-15 1997-07-24 Antonio Picarelli Preparato per il trattamento dell'obesita'
CA2215387A1 (en) 1995-03-20 1996-09-26 Michael R. Briggs Modulators of ob gene and screening methods therefor
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US6090836A (en) 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
ATE262334T1 (de) 1996-02-02 2004-04-15 Merck & Co Inc Antidiabetisches mittel
US5803916A (en) 1996-03-19 1998-09-08 Vital-Tech Ltd. Body and joints massage device
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US5830916A (en) * 1996-05-23 1998-11-03 Duke University Inhibitor of ceramidase
US5856537A (en) 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
US5925672A (en) 1996-12-06 1999-07-20 Neurosciences Research Foundation, Inc. Methods of treating mental diseases, inflammation and pain
US6160000A (en) 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6090839A (en) 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
US5985282A (en) * 1997-01-22 1999-11-16 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6008237A (en) 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
DE69927496T2 (de) 1998-05-29 2006-07-06 Neurosciences Research Foundation, San Diego Schmerzlinderung mit endogenen cannabinoiden
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US6274608B1 (en) 1999-04-20 2001-08-14 Novo Nordisk A/S Compounds, their preparation and use
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US6359010B1 (en) 1999-11-23 2002-03-19 Thomas D. Geracioti, Jr. Methods of treating anxiety and mood disorders with oleamide
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
EP1294411A4 (en) 2000-05-23 2006-02-01 Univ California COUGH TREATMENT
WO2002080860A2 (en) 2001-03-27 2002-10-17 The Regents Of The University Of California Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
US7048941B2 (en) 2001-03-30 2006-05-23 New World Enterprizes, Inc. Chocolate composition as delivery system for nutrients and medications
AU2002309548B2 (en) * 2001-04-06 2006-08-10 The Board Of Trustees Of The University Of Illinois Functional role for cannabinoids in autonomic stability during sleep
WO2003011220A2 (en) * 2001-07-31 2003-02-13 The Scripps Research Institute Animal model for fatty acid amide-related neurobehaviors
EP1472215A4 (en) 2002-02-08 2007-05-09 Bristol Myers Squibb Co (OXIME) CARBAMOYL, FATTY ACID AMIDE HYDROLASE INHIBITORS
US20040157932A1 (en) 2002-11-18 2004-08-12 Natural Asa, Supplements and foods comprising oleylethanolamide

Also Published As

Publication number Publication date
WO2002080860A2 (en) 2002-10-17
AU2002338329B2 (en) 2006-09-07
KR20030087657A (ko) 2003-11-14
CA2442683A1 (en) 2002-10-17
US20090005447A1 (en) 2009-01-01
US6911474B2 (en) 2005-06-28
WO2002080860A3 (en) 2004-02-26
US7423066B2 (en) 2008-09-09
JP2004526745A (ja) 2004-09-02
EA200301057A1 (ru) 2004-04-29
AU2002338329C1 (en) 2002-10-21
EA006556B1 (ru) 2006-02-24
CN1523982A (zh) 2004-08-25
IL158131A0 (en) 2004-03-28
US20050187254A1 (en) 2005-08-25
EP1408945A4 (en) 2005-07-06
EP1408945A2 (en) 2004-04-21
US20030018081A1 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
MXPA03008823A (es) Metodos, compuestos y composiciones para reducir la grasa corporal y modular el metabolismo de los acidos grasos.
WO2005046580A3 (en) Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism
AR042107A1 (es) Composiciones dieteticas
BR9907189A (pt) Produtos da fração lipìdica do carotenóide de pepino do mar e métodos de uso
IL198137A0 (en) Ketogenic diet
BRPI0515316A (pt) compostos de imidazoquinolina
MXPA04009741A (es) Metodo y composicion dietaria para mejorar la digestibilidad de grasas.
WO2003041681A3 (en) Lipid carrier compositions with enhanced blood stability
DE60331319D1 (de) Nahrungs- oder pharmazeutische zusammensetzungen zur erhöhung der creatin-antwort von organismen
PT920323E (pt) Nova utilizacao de fosfolipidos de origem animal em terapeutica e/ou dietetica
MXPA04001129A (es) Mezclas de lipidos y productos de alimento que contienen acido graso oleico y acidos grasos omega-6, disenadas para incrementar el nivel intramiocelular de lipidos.
PL378238A1 (pl) Związki biaromatyczne, które aktywują receptory typu PPAR<$Egamma>, oraz ich zastosowanie w kompozycjach kosmetycznych albo farmaceutycznych
BR0110664A (pt) Composição de gordura alimentìcia escoável, e, uso de uma combinação de um éster de ácido cìtrico de glicerìdeos parciais de ácido graxo e um sal
NO20024722D0 (no) Stivelses-subtyper og lipid metabolisme
BR0309421A (pt) Composições de proteìna associada com corpo oleoso e métodos de uso destas para reduzir o risco de doença cardiovascular
AR031962A1 (es) Induccion de tolerancia
BR9909234A (pt) Método para fornecimento de glutamina
ATE334685T1 (de) Verwendung von phosphatidylserin zur behandlung des aufmerksamkeits-defizit-syndroms (adhs)
BR0213299A (pt) Utilização de cistationina
ATE253927T1 (de) Wirkstoff für verbesserten fettstoffwechsel
WO2005063205A3 (en) Injectable phosphatidylcholine preparations
ATE358992T1 (de) Enteralpräparat zur vorbeugung gegen bzw. behandlung von sepsis
CA2343116A1 (en) Methods and compositions for increasing intestinal absorption of fats
MY126526A (en) Pharmaceutical formulations
MX2007012699A (es) Componenetes lacteos estables eficaces para la perdida de grasa.

Legal Events

Date Code Title Description
FG Grant or registration